OsteGro V joins Aziyo’s viable bone matrix platform targeted at supporting bone repair, which currently includes the Company’s ViBone and FiberCel product lines. As part of its commercial strategy for OsteGro V, Aziyo has entered into several non-exclusive private label distribution agreements. The agreements are expected to drive adoption and penetration in the orthopedic, spinal, and dental markets.
“As we continue expand our portfolio of viable bone matrix products, we are pleased to be collaborating with multiple partners to deliver our newest generation of OsteGro that contains native bone cells,” said Ron Lloyd, president and CEO, Aziyo Biologics. “We are looking forward to leveraging our biologic expertise as well as our partners’ breadth of commercial expertise. These agreements illustrate our ongoing commitment to working with commercial partners to add innovative product options for orthopedic surgeons and their patients.”
The launch of OsteGro V deepens Aziyo’s portfolio of advanced regenerative products spanning the implantable electronic devices/cardiovascular market, the ortho/spinal repair market, and the soft tissue reconstruction market.
Last Fall, Aziyo Biologics signed an exclusive, multi-year distribution agreement with Medtronic for the U.S. orthopedic market. Per the agreement, Aziyo will manufacture and supply FiberCel to Medtronic for distribution through the company’s sales and marketing organization.
FiberCel is a bone repair product made from human tissue utilizing Aziyo’s long standing bone repair matrix manufacturing expertise. Engineered to be like natural tissue, FiberCel provides improved handling properties critical for use as a bone void filler in various orthopedic procedures. The product contains cancellous bone particles with preserved living cells and demineralized cortical bone fibers combined using Aziyo’s proprietary manufacturing processes to create a unique and innovative solution. FiberCel is another example of Aziyo’s commitment to preserve the natural properties of their orthopedic regenerative tissue products portfolio through cell health preservation and bone fiber optimization techniques.